Main Article Content
Objective: To determine the effectiveness of oral eplerenone in the treatment of chronic central serous chorioretinopathy (CSC).
Methodology: This non-randomized controlled trial conducted in Out Patient Department of Ophthalmology, Hayatabad Medical Complex, Peshawar from October 2015 to September 2016. 32 eyes of 32 patients who were diagnosed as cases of chronic CSC were included in the study. In all patients, visual acuity was recorded and the dilated fundoscopy was done followed by spectral domain optical coherence tomography (OCT) of macula to confirm the diagnosis. The macular thickness and subretinal fluid diameter was calculated using Spectralis OCT calipers. All patients were started on oral eplerenone 25mg once daily. All patients were reviewed after 1 month and 3 months with repeated OCT scans and visual acuity, OCT and fundus examination.
Results: Study was conducted on 32 eyes of thirty two patients. Mean age was 33.5 ±6.74 years. The mean baseline central macular thickness was 434.90 ±53.27µ. After 3 months, significant improvement in visual acuity was documented. There was marked reduction in central macular thickness after three months with mean of 325.41 ±52.55µ.
Conclusion: Oral eplerenone was an effective treatment for chronic serous dhorioretinopathy in terms of both anatomic and visual improvement.
Work published in JPMI is licensed under a
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.